Rivastigmine–Benzimidazole Hybrids as Promising Multitarget Metal-Modulating Compounds for Potential Treatment of Neurodegenerative Diseases

David Vicente-Zurdo,Leonardo Brunetti,Luca Piemontese,Beatriz Guedes,Daniel Chavarria,Fernanda Borges,Yolanda Madrid,Sílvia Chaves,Sandra M. Cardoso,M. Amélia Santos

DOI: https://doi.org/10.3390/ijms24098312

IF: 5.6

2023-05-05

International Journal of Molecular Sciences

Abstract:With the goal of combating the multi-faceted Alzheimer’s disease (AD), a series of Rivastigmine-Benzimidazole (RIV–BIM) hybrids was recently reported by us as multitarget-directed ligands, thanks to their capacity to tackle important hallmarks of AD. In particular, they exhibited antioxidant activity, acted as cholinesterase inhibitors, and inhibited amyloid-β (Aβ) aggregation. Herein, we moved forward in this project, studying their ability to chelate redox-active biometal ions, Cu(II) and Fe(III), with widely recognized roles in the generation of oxidative reactive species and in protein misfolding and aggregation in both AD and Parkinson’s disease (PD). Although Cu(II) chelation showed higher efficiency for the positional isomers of series 5 than those of series 4 of the hybrids, the Aβ-aggregation inhibition appears more dependent on their capacity for fibril intercalation than on copper chelation. Since monoamine oxidases (MAOs) are also important targets for the treatment of AD and PD, the capacity of these hybrids to inhibit MAO-A and MAO-B was evaluated, and they showed higher activity and selectivity for MAO-A. The rationalization of the experimental evaluations (metal chelation and MAO inhibition) was supported by computational molecular modeling studies. Finally, some compounds showed also neuroprotective effects in human neuroblastoma (SH-SY5Y cells) upon treatment with 1-methyl-4-phenylpyridinium (MPP+), a neurotoxic metabolite of a Parkinsonian-inducing agent.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop a new multi - target drug for the treatment of neurodegenerative diseases, especially Alzheimer's disease (AD) and Parkinson's disease (PD). Specifically, the researchers designed and synthesized **Rivastigmine - Benzimidazole (RIV - BIM) hybrid compounds**, which have the following characteristics:

1. **Metal - chelating ability**: They are able to chelate active metal ions (such as Cu(II) and Fe(III)), and these metal ions are related to oxidative stress and protein misfolding in AD and PD.
2. **Cholinesterase inhibitory effect**: As inhibitors of cholinesterase (AChE and BChE), they help to improve cognitive function.
3. **Inhibition of amyloid - beta (Aβ) aggregation**: They reduce the aggregation of Aβ, which is an important pathological feature of AD.
4. **Antioxidant activity**: They provide antioxidant protection and reduce the damage of oxidative stress to nerve cells.
5. **Monoamine oxidase (MAO) inhibitory effect**: Especially the inhibitory effect on MAO - A, which helps to treat PD.

Through these properties, the RIV - BIM hybrid compounds aim to act on multiple pathological mechanisms simultaneously, so as to treat complex neurodegenerative diseases more effectively. In addition, the study also evaluated the neuroprotective effects of these compounds in in - vitro models, especially the protective effect in 1 - methyl - 4 - phenylpyridinium (MPP+) - induced human neuroblastoma (SH - SY5Y) cell damage.

Overall, the goal of this paper is to develop a new drug with multi - target effects to deal with the complex pathological mechanisms of AD and PD.